-
Product Insights
NewHuman Papillomavirus Infections – Drugs In Development, 2024
Empower your strategies with our Human Papillomavirus Infections – Drugs In Development, 2024 report and make more profitable business decisions. Human Papillomavirus (HPV) infections are common sexually transmitted infections caused by the HPV virus. There exist over 100 types, some leading to genital warts, while others increase the risk of various cancers, including cervical, anal, and throat cancers. Often asymptomatic, HPV can spread through sexual contact, including skin-to-skin contact. Vaccines effectively prevent many high-risk HPV types, reducing infection and cancer risk....
-
Product Insights
NewRespiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024
Empower your strategies with our Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Respiratory syncytial virus (RSV) infection is a respiratory disease. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache, and fever. Treatment includes proper medication and hygiene practice. The Respiratory Syncytial Virus...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PV-001 in Human Papillomavirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PV-001 in Human Papillomavirus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PV-001 in Human Papillomavirus Infections Drug Details: PV-001 is under development...
-
Product Insights
Human Papillomavirus (HPV) Associated Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Risk factors of Human Papillomavirus (HPV) Associated Cancer includes smoking, weakened immune system, long-term oral contraceptive use, and chronic inflammation. The Human Papillomavirus (HPV) Associated Cancer pipeline drugs market research report provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule...